A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 10085-10096

  Ji, Xiaonan ^a   Shen, Yanli ^b   Sun, Hao ^a   Gao, Xiangdong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b The People s Hospital of Pizhou   (China)

Author keywords

Alpha fetoprotein; Apoptosis; Cell cycle arrest; Hepatocellular carcinoma; Single chain variable fragment

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN ANTIBODY; ALPHA FETOPROTEIN SINGLE CHAIN VARIABLE FRAGMENT ANTIBODY; ANTINEOPLASTIC AGENT; FLUOROURACIL; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; HEP-G2 CELL LINE; IMMUNOLOGY; LIVER; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; RANDOMIZATION; TUMOR CELL LINE;

ALPHA-FETOPROTEINS; ANIMALS; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PACLITAXEL; RANDOM ALLOCATION; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955575578     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4803-x     Document Type: Article

References (28)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. EASL-EORTC clinical practice guidelines. Management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
4. Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis. 2011;15:423–41. vii-x.
5. Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, Sakamoto M, Tsuchiya R, et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol. 2003;33:522–6.
6. Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma bel 7402 cells. World J Gastroenterol. 2004;10:819–24.
7. Ma WJ, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol. 2013;11:212.
8. Hann HW, Fu X, Myers RE, Hann RS, Wan S, Kim SH, et al. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis b virus infection—results from a clinic-based longitudinal cohort. Eur J Cancer. 2012;48:2319–27.
9. Zhu M, Guo J, Li W, Lu Y, Fu S, Xie X, et al. Hepatitis b virus × protein induces expression of alpha-fetoprotein and activates PI3K/MTOR signaling pathway in liver cells. Oncotarget. 2015;6:12196–208.
10. Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, et al. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol. 2011;17:4563–71.
11. Mizejewski GJ. Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family. Tumour Biol. 2011;32:241–58.
12. Zhu M, Guo J, Li W, Xia H, Lu Y, Dong X, et al. HBX induced AFP receptor expressed to activate PI3K/Akt signal to promote expression of SRC in liver cells and hepatoma cells. BMC Cancer. 2015;15:362.
13. Li M, Li H, Li C, Wang S, Jiang W, Liu Z, et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/Akt signaling in human hepatoma cell lines. Int J Cancer. 2011;128:524–32.
14. Zhu M, Guo J, Xia H, Li W, Lu Y, Dong X, et al. Alpha-fetoprotein activates Akt/MTOR signaling to promote CXCR4 expression and migration of hepatoma cells. Oncoscience. 2015;2:59–70.
15. Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, et al. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of FN14 in human hepatocellular carcinoma. J Hepatol. 2012;57:322–9.
16. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11:636–46.
17. Mohr SE, Perrimon N. RNAi screening: new approaches, understandings, and organisms. Wiley Interdiscip Rev RNA. 2012;3:145–58.
18. Perez-Martinez D, Tanaka T, Rabbitts TH. Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays. 2010;32:589–98.
19. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. SCFV antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.
20. Neri D, Petrul H, Winter G, Light Y, Marais R, Britton KE, et al. Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase ii and [gamma-32p]-ATP. Nat Biotechnol. 1996;14:485–90.
21. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350–4.
22. Li H, Liu H, Wang Z, Liu X, Guo L, Huang L, et al. The role of transcription factors SP1 and YY1 in proximal promoter region in initiation of transcription of the mu opioid receptor gene in human lymphocytes. J Cell Biochem. 2008;104:237–50.
23. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin. 2004;25:146–7.
24. Li M, Zhou S, Liu X, Li P, McNutt MA, Li G. Alpha-fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Lett. 2007;249:227–34.
25. Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumour Biol. 2013;34:2075–91.
26. Mizejewski GJ. Nonsecreted cytoplasmic alpha-fetoprotein: a newly discovered role in intracellular signaling and regulation. An update and commentary. Tumour Biol. 2015;36:9857–64.
27. Tian A, Wilson GS, Lie S, Wu G, Hu Z, Hebbard L, et al. Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Lett. 2014;351:232–41.
28. Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, et al. Targeted inhibition of phosphatidyl inositol-3-kinase p110beta, but not p110alpha, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis. 2013;18:509–20.